ArticleTherapeutic advances in respiratory disease
Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision treatment of COPD based on novel imaging phenotypes: a treatable traits approach.Respiratory research · 2026Review
- Identification of imaging-based pulmonary and extrapulmonary treatable traits in COPD: a review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype is linked to frequent exacerbations and increased oral corticosteroid (OCS) use. Mepolizumab, an anti-IL-5 monoclonal antibody, has shown efficacy in eosinophilic airway disease. This study assessed its real-life effectiveness in COPD patients with frequent OCS-requiring exacerbations.
objectivesTo evaluate the effectiveness of mepolizumab in reducing exacerbations and corticosteroid use in eosinophilic COPD patients in a real-world setting.
designRetrospective, single-centre cohort study with two-year follow-up.
methodsThe study included 13 consecutive COPD patients treated with mepolizumab (100 mg SC every 4 weeks) from 2020 to 2022 and followed for two years. Inclusion required ⩾2 OCS-treated exacerbations or maintenance OCS use in the prior year and blood eosinophils > 300 cells/µL. Response was defined as a ⩾50% reduction in annual OCS-requiring exacerbations.
resultsAt one year, 9 of 13 patients (69%) were responders. Median annual moderate-to-severe exacerbations decreased from 4.0 (IQR: 1.5-10.0) to 1.0 (IQR: 0.0-2.0;
conclusionMepolizumab significantly reduced exacerbations and hospitalizations in eosinophilic COPD patients with frequent OCS use. A 69% response rate at one year and sustained benefit in the second year support its role in this difficult-to-treat population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.